PPARG and metabolic dysfunction-associated steatohepatitis: In addition, as we are moving towards individualized medicine, these data could provide the basis to design pharmacogenetic studies to address whether the therapeutic efficacy of PPARγ agonists in patients NASH is affected by the PPARγ2 12Ala SNP.